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Blood-borne monocyte derived cells play a pivotal, initially unrecognized, role in most 
central nervous system disorders, including diseases initially classified as purely neuro-
degenerative (i.e., Alzheimer’s disease, Parkinson’s disease, and ALS). Their trafficking 
to the brain and spinal cord has been extensively studied in classical neuroinflammatory 
disorders such as multiple sclerosis. Central nervous system resident myeloid cells, 
namely microglia and perivascular macrophages, also are in the spotlight of investigations 
on neurological disorders. Myeloid cells, such as infiltrating macrophages and microglia, 
have been described as having both protective and destructive features in neurological 
disorders, thus identification of their functional phenotype during disease evolution 
would be of paramount importance. Extracellular vesicles, namely exosomes and shed 
vesicles, are released by virtually any cell type and can be detected and identified in 
terms of cell origin in biological fluids. They therefore constitute an ideal tool to access 
information on cells residing in an inaccessible site such as the brain. We will review here 
available information on extracellular vesicles detection in neurological disorders with 
special emphasis on neurodegenerative diseases.
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iNTRODUCTiON
Phagocytes, and in particular macrophages and microglia, are in the spotlight of investigations on 
the pathogenesis of neurodegeneration, involving disorders such as the progressive phase of multiple 
sclerosis (MS) and more classical neurodegenerative diseases such as Alzheimer’s and Parkinson’s 
disease (AD and PD). While in all these cases, classical anti-inflammatory therapies have failed, 
and there is no doubt that an inflammatory component is always present. The hypothesis that 
malfunctioning or dysregulated myeloid cells are the cause of chronic inflammation associated to 
neurodegeneration also derives from the knowledge that the innate immune system is highly plastic. 
In this respect, it may control the initiation of the inflammatory process as well as transition from a 
purely destructive process to termination of inflammation and tissue reconstruction. Data available 
in the literature do not compose a coherent picture for several reasons. Inflammation is clearly a 
protective process, and it is difficult to identify and distinguish the altered component, if present. 
Second, there are numerous different myeloid cells in the brain, such as microglia, infiltrating and 
perivascular macrophages and dendritic cells. All are very plastic in their functional phenotype and 
endowed with peculiar abilities, playing different roles during neuroinflammation. This confusing 
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picture has lead to the common use of an oversimplified defini-
tion of these functional phenotypes (M1 =  pro-inflammatory; 
M2 = anti-inflammatory and pro-reparative) and to a superficial 
definition of their role in the pathogenesis of neurodegeneration 
(M1  =  detrimental; M2  =  protective). Data in experimental 
models, however, are not in accordance with this straightforward 
working hypothesis, and the M1/M2 paradigm is no longer the 
consensus in the field, knowing that the myeloid cell phenotype 
in  vivo is very complex. Data in the human setting are, how-
ever, very difficult to obtain since there is currently no way to 
investigate the functional phenotype of CNS-resident myeloid 
cells during disease development. Taking AD as a prototypical 
example, we will try in the present review to suggest a possible 
line of investigation able to contribute novel data on the role of 
myeloid cells during neurological disorders.
MYeLOiD CeLLS PHeNOTYPe iN AD
While for decennia, the focus of research in AD had been almost 
exclusively on the mechanisms leading to extracellular accumula-
tion of the amyloid β peptide 1–42 (Aβ1–42) and the deposit of 
neurofibrillary tangles (NFTs), more recently several investiga-
tors have explored the role of the immune system in AD. The 
inflammatory response associated with AD is primarily driven by 
the resident cells of the brain such as microglia, perivascular mac-
rophages, and reactive astrocytes and by non-CNS resident cells 
like monocytes/macrophages. It is not very clear when inflam-
matory response starts in AD. It was originally assumed that 
neuroinflammation occurs only at late stages of AD and that glial 
cell activation accompanies but does not significantly contribute 
to amyloid pathology (1, 2). More recent data, mostly from the 
debated genetic mouse models of AD, indicate that the involve-
ment may be more precocious (3). It appears reasonable to think 
that microglia is the first myeloid cell to be activated during AD, 
but the CNS has a rich complement of non-microglial myeloid 
cells including meningeal and choroid plexus macrophages, as 
well as perivascular macrophages. Of these, perivascular mac-
rophages seem to have a particularly crucial role in the physi-
ological removal of Aβ1–42 and protection from amyloid pathology 
(4) and are continuously replaced by circulating monocytes. Both 
macrophages and microglia cells can be polarized into M1 and M2. 
This activation is dynamic and plastic and built up in response to 
the changes of the microenvironment. Phenotypic classification 
of macrophages is further hampered by the lack of exclusivity of 
some of the classical M1 and M2 marker, and by the difficulty to 
overlap it with functional classification (inflammatory vs. wound 
healing vs. regulatory macrophages) (5). The identification of 
new phenotypic markers may allow to overcome these difficulties 
in the near future (6, 7). Using conventional markers, both M1 
and M2 phenotypes co-exist during both early and late AD (3), 
possibly linked to slightly different disease phenotypes (8). The 
very lively debate on the role of myeloid cells during neurodegen-
eration is caused by the uncertainties on their actual activation 
phenotype during disease development. This is due to the lack 
of handy investigation tools, such as appropriate biomarkers, to 
assess microglia activation in vivo, with the notable exception of 
PET imaging using the tracer [11C] (R)-PK11195 (9). The latter, 
however has low resolution and does not provide any information 
on the myeloid cell and activation phenotype.
eXTRACeLLULAR veSiCLeS TO 
iNveSTiGATe MiCROGLiA
In the experimental mouse model for multiple sclerosis (MS) 
and in human MS patients, we described that microglia release 
microvesicles that can be detected in the CSF and that can con-
tribute to disease pathogenesis by delivering a pro-inflammatory 
signal (10).
The recent discovery that cell-derived extracellular microvesi-
cles (EVs) are not artifactual in vitro entities, as considered for 
many years, has somehow revolutionized the field of cell-to-cell 
communication. There is a growing interest of researchers for 
microvesicles, and it seems that there is no field of biomedicine 
where they are not investigated.
Circulating EVs contribute to the development of cancer, auto-
immune, and cardiovascular diseases, and the elevated number of 
shedding vesicles in plasma and/or other biological fluids (CSF, 
saliva, amniotic fluid, synovial fluid, breast milk, and urine) (11) 
correlates with the acute or active phase of many diseases (tumor 
progression, tissue destruction, etc.), suggesting that they can be 
used as potential predictive and diagnostic biomarkers for a large 
number of pathologies.
So far, two main EVs types have been isolated and described 
according to their different size and density: shedding vesicles 
and exosomes. Shedding vesicles are 100–1000 nm sized vesicles 
derived from the cell plasma membrane upon surface bending 
and budding as a consequence of lipid scrambling and cytoskel-
eton remodeling (Figure 1). These deep but reversible structural 
changes are the final step of a complex signaling network that 
has not been clarified yet. Shedding vesicles biogenesis is strongly 
enhanced by extracellular ATP and its structural analogs (1) as 
well as by some other few “unphysiological” triggers such as 
calcium ionophores or phorbolester derivatives (12) whose 
overall effect consists in rising the cytosolic calcium levels. On 
the other hand, exosomes are nanovesicles (20–100  nm) of 
endosomal origin, as they are generated by the invagination of 
the late endosomes membrane. Resulting organelles have been 
defined as multivesicular bodies whose intraluminal vesicles are 
the exosomes. The exocytosis of multivesicular bodies eventually 
culminates in the release of exosomes outside the cell. The interest 
and excitement for EVs has been sudden and exponential, leading 
to confusion in the nomenclature and classification of micropar-
ticles necessitating urgent revision for the sake of clarity in the 
field (13, 14). The molecular composition of shedding vesicles 
and exosomes is highly heterogeneous, but similar to the cells 
of origin. Their content includes proteins (signaling molecules, 
receptors, integrins, and cytokines), bioactive lipids, nucleic acids 
(miRNA, mRNA, and DNA), and organelles (15) through which 
they can influence recipient cells (11).
This influence is relevant in physiology, but of course also 
during pathology. Particularly relevant is the influence on the 
immune system, the system devoted to protect tissues from 
insults and to foster regenerative processes. Extracellular vesicles 
FiGURe 1 | electron microscopy of extracellular vesicles. The human 
microglia cell line, CHME-5 was stimulated with ATP to induce release of EVs. 
Supernatant was analyzed by transmission electron microscopy. Integrity, 
round shape, and lipid bilayer of the membrane (approximately 7 nm) can be 
appreciated from the picture of this shed vesicle of about 250 nm of 
diameter.
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are involved in all immune activities, and thus their effect in 
neurological disorders can be protective or detrimental, as the 
influence of the immune system itself (16).
eXTRACeLLULAR veSiCLeS iN 
ALZHeiMeR’S DiSeASe
Multiple lines of research indicate that extracellular vesicles are 
involved in the pathogenesis of AD. To date, the potential role of 
EVs in AD is object of debate and evidences for either beneficial 
or detrimental action have been reported (17–26).
Yuyama and co-workers have recently suggested a neuropro-
tective role of EVs in AD describing a novel function for exosomes 
as scavengers of neurotoxic Aβ (21). In particular, addition of an 
exosome/Aβ mixture to primary cortical cells significantly sup-
pressed the formation of toxic oligomers and neuronal toxicity 
revealing the capability of exosomes to trap Aβ and to promote 
its clearance by microglia (27). Additionally, Aβ pathology and 
amyloid deposition diminished following intracerebral infusion 
of exosomes isolated from cultured neuroblastoma cells in a 
mouse model of AD (20). These findings suggest a coordinated 
mechanism by which neurons and neighboring microglia use 
exosomes to clear Aβ1–42. Authors proposed to use exosomes as a 
novel therapeutic approach to prevent plaque deposition in AD 
(21). The potential neuroprotective role of exosomes in AD is 
consistent with a recent study on a mouse model of familial AD. 
In this study, the presence of presenilin-2 mutations is associated 
with reduced ability of neurons to eliminate cystatin C, APP, and 
their toxic metabolites trough exosomes (25). Recent reports 
focused on role of neprilysin in AD pathology, supporting a 
scenario in which neprilysin-loaded exosomes contribute to Aβ 
clearance in the brain. Accordingly, a recent study demonstrated 
for the first time that adipose tissue-derived mesenchymal stem 
cells produce neprilysin-bound exosomes. Co-culture experi-
ments indicated that mesenchymal stem cells-derived exosomes 
contributed to decrease of the secreted Aβ levels in N2a cells, sug-
gesting a therapeutic potential of microvesicle-bound neprilysin 
for AD treatment (28).
On the other hand, the neurotoxic role of EVs was initially 
proposed after the observation that Aβ species involved in AD 
can be encapsulated into neuronal exosomes to be released in the 
extracellular space. Aβ1–42 is generated in early endosomes, sorted 
to multivesicular bodies in APP-expressing neuroblastoma cells, 
and released via exosomes after fusion of multivesicular bodies 
with the plasma membrane into the extracellular environment 
(29, 30). The identification of exosome-associated proteins, 
such as Alix and flotillins, in amyloid plaques in the brains of 
mice (31) and post-mortem human AD patients (29) supports 
a role for exosomes in spreading Aβ1–42 aggregates to these sites 
during disease progression and represents a novel mode of 
amyloid transmission (32). Further evidence of a potential role 
of exosomes in AD comes from recent studies demonstrating 
that also proteins and peptides, such as APP, APP C-terminal 
fragments, APP intracellular domain, associated with AD, can 
be selectively released in association with exosomes and can 
contribute to the pathology (29, 30, 33).
The neurotoxic role of EVs in AD is also sustained by data 
showing the increase of microglial EVs production in patients 
with neurodegenerative diseases (17, 18). Recently, our group 
demonstrated that the increase of EVs derived from myeloid 
cells (IB4+) measured in CSF of AD and mild cognitive impair-
ment (MCI) patients correlates with classical biomarkers of 
neuronal injury (i.e., t-Tau, p-Tau, and Aβ1–42), demonstrating 
the diagnostic potential of EVs (18). Notably, CSF EVs levels 
were positively associated with white matter damage in MCI 
patients and hippocampal atrophy in AD patients, as detected 
by MRI (18). Accordingly, high levels of p-Tau associated with 
exosome have been found in blood of patients with prodromal 
AD (34). Moreover, EVs released by microglia exposed to Aβ1–42 
in  vitro promote formation of soluble neurotoxic Aβ1–42 spe-
cies from extracellular insoluble aggregates in neuron cultures 
thereby acting as potent drivers of neuronal damage (17). The 
observation that microglia release Aβ species in association 
with EVs, together with the evidence that activated microglia 
constantly surround amyloid deposits (35) suggests the existence 
of a potential mechanism of cell–cell communication by which 
EVs spread Aβ pathology through the brain. EVs seem to be 
involved also in the diffusion of aggregated Tau during AD (36, 
37). In a recent study, Saman and co-workers (36) show that 
CSF exosomes from AD patients contain hyperphosphorylated 
oligomeric tau secreted by neurons, suggesting that exosome-
mediated secretion of phosphorylated tau may play a significant 
FiGURe 2 | Polarized myeloid cells release polarized microvesicles. 
Murine macrophages were polarized in the presence of IFN-γ [M1 (A)] or IL-4 
[M2 (B)] and stained with anti-IB4 (green), anti-Iba-1 (blue), anti-CD206 (red), 
and DAPI (gray). IB4 stains all myeloid cells, Iba-1 is an M1 marker and is 
up-regulated in (A) while CD206, an M2 marker, is up-regulated in (B). 
Arrows in (A,B) indicate putative shed vesicles (of approximately 1 μm of 
diameter) displaying polarization markers similar to their.
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role in the abnormal processing of tau and in the genesis of 
elevated CSF tau in early AD. Notably, microglia may also 
facilitate tau protein propagation to neurons by phagocyting and 
secreting tau protein in exosomes (38). Nevertheless, the role of 
EVs in protein-aggregation diseases requires further investiga-
tions (24).
Overall, increased levels of EVs in the CSF, together with 
altered value of soluble proteins in AD patients, may represent 
an emerging strategy for the identification of possible predic-
tive biomarkers and/or therapeutic targets for AD. There is no 
doubt, however, that additional information may be gained by 
analyzing the EVs content. While, in fact, available data link the 
release of EVs in the CSF to microglia activation, we still do not 
have a tool to investigate the functional phenotype of activated 
microglia. In particular, toxic or protective role of EVs in AD 
may be linked to the functional phenotype of their parent cells. 
Since EVs represent, in their content, the cell of origin, microglia 
microvesicles are potentially the source of this information. Our 
group provided proof of principle for myeloid cells showing how 
M1 and M2 markers in microvesicles allow the identification 
of the phenotype of parental macrophages, in vitro and in vivo 
(Figure 2) (39).
CONCLUSiON
There is a growing interest in myeloid cells in neurodegenera-
tive disorders such as the progressive forms of MS, AD, PD, and 
ALS. In general terms, this originates from the presence of an 
immune/inflammatory signature in all of these diseases on one 
side and on the failure of classical anti-inflammatory or even 
immune-suppressive treatments on the other. CNS-resident 
and CNS-infiltrating myeloid cells are able to modify their phe-
notype according to the environment in a matter of hours and 
their location behind the blood brain barrier makes the scarcely 
accessible to current treatments. The variety of activation pat-
terns and stimuli of these cells and the lack of knowledge on their 
involvement in neurodegeneration leaves open the door to all 
sorts of speculations on their protective rather than pathogenic 
role in neurodegeneration. Investigating their biology and their 
behavior would be possible in experimental mouse models, but 
both the model for progressive MS and those for neurodegen-
erative diseases, such as AD, are scarcely representative of the 
final effector mechanisms affecting neurons. Neurodegeneration 
is indeed substantially absent or very poor in these models. In 
human patients, on the other side, to investigate CNS myeloid 
cells is extremely difficult. We think that myeloid extracellular 
vesicles, representing a “liquid biopsy” of their parental cells, may 
provide the answers to some of the many question open in this 
field. Knowing the functional phenotype of myeloid cells during 
the development of neurological disorders would at least allow 
to start to investigate their role, protective or damaging, during 
pathogenic processes. The development of appropriate technolo-
gies able to detect, sort, and analyze microvesicles in biological 
fluids is the necessary pre-requisite. There is considerable pres-
sure to reach these goals, given the implication this would have for 
relevant fields such as oncology. The sorting and analysis of extra-
cellular vesicles released by neural or CNS-infiltrating cells would 
be, however, of paramount importance for clinical neurosciences, 
providing information on an otherwise almost inaccessible organ.
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